Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
MEI Pharma, Inc., an advanced stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San Diego, California.
52W High
$8.25
52W Low
$1.46
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.22
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.58
EV/Revenue (<3 favorable)
1.39
P/S (TTM) (<3 favorable)
0.28
P/B (<3 favorable)
7.11
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
8.35%
Institutions (25–75% balanced)
8.93%
Shares Outstanding
32,837,700
Float
6,171,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
2023-11-16
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-5,593,000
EPS (TTM)
-4.75
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.90%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—